Log In
BCIQ
Print this Print this
 

IC14

  Manage Alerts
Collapse Summary General Information
Company Implicit Biosciences Pty. Ltd.
DescriptionRecombinant chimeric mAb against CD14
Molecular Target CD14
Mechanism of ActionBinds CD14; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationAcute lung injury
Indication DetailsTreat acute lung injury
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/02/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today